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Background: Gastric cancer remains the second leading cause of cancer-related deaths in the world. Successful
early gastric cancer detection is hampered by lack of highly sensitive and specific biomarkers. Plasma membrane
proteins participate and/or have a central role in the metastatic process of cancer cells and are potentially useful for
cancer therapy due to easy accessibility of the targets.
Methods: In the present research, TMT method followed by mass spectrometry analysis was used to compare the
relative expression levels of plasma membrane proteins between noncancer and gastric cancer tissues.
Results: Of a total data set that included 501 identified proteins, about 35% of the identified proteins were found
to be plasma membrane and associated proteins. Among them, 82 proteins were at least 1.5-fold up- or down-regulated
in gastric cancer compared with the adherent normal tissues.
Conclusions: A number of markers (e.g. annexin A6, caveolin 1, epidermal growth factor receptor, integrin beta 4)
were previously reported as biomarkers of GC. Additionally, several potential biomarkers participated in endocytosis
pathway and integrin signaling pathways were firstly identified as differentially expressed proteins in GC samples. Our
findings also supported the notion that flotillin 1 is a potential biomarker that could be exploited for molecular
imaging-based detection of gastric cancer. Together, the results show that subcellular proteomics of tumor tissue is a
feasible and promising avenue for exploring oncogenesis.
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Gastric cancer(GC) is the second leading cause of
cancer related deaths which kill about 800 000 people
annually [1]. It is a highly aggressive malignant disease
with the overall 5 year survival rate (5YSR) of 24% [2].
The major reason for this poor outcome is the
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tients. Therefore, the identification of tumor
biomarkers for early detection plays an important role
in improving diagnosis and treatment of GC. Unfortu-
nately, tumor biomarkers such as CEA and CA19-9
that are currently utilized for the detection of GC in
clinical practice are not specific and sensitive enough;
with their sensitivity in the range of 18%–57% [3].
Consequently, discovery of the valuable biomarkers of
GC remains a worthy task.
Plasma membrane encloses the cell and maintains the
essential boundaries between the cytosol and the extra-
cellular environment. The proteins constitute approxi-
mately 50% (by mass) of the cell surface membrane [4].
Proteins located in plasma membrane mediate most
functions of the membrane, such as acting as sensors fordistributed under the terms of the Creative Commons Attribution 4.0
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ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Gao et al. BMC Cancer  (2015) 15:367 Page 2 of 14external signals, transporters of specific molecules and
the connection point of the membrane to the cytoskel-
eton, the extracellular matrix and adjacent cells [5,6].
Significantly, these proteins constitute more than 45% of
current drug targets, with 25–30% of drugs targeting G-
protein coupled receptors [7,8]. Defining the plasma
membrane proteome is of great interest due to the fun-
damental role of membrane proteins [9]. Moreover, pro-
filing plasma membrane markers in specific disease
stage has great potential for identifying novel biomarkers
and subsequent therapeutic targets [8]. Her2 [10], c-
Met, and EGFR [11] are classical examples of plasma
membrane proteins against which small molecules and
biologics have been successfully developed and imple-
mented in the clinic [10-12]. Attempts have succeeded
in identifying potential plasma membrane biomarkers
of GC from cell lines. These include but are not limited
to SLC3A2. However, global proteomic analysis of
membrane-enriched samples from normal versus GC
tissues has not been reported before.
Stable isotope-based quantitative proteomics approach
for identification and quantification of proteins has pro-
vided new possibilities in the field of biomarker discov-
ery [13]. The isotopes can be incorporated metabolically
as in SILAC or chemically as in isobaric labeling methods
include isobaric tag for relative and absolute quantification
(iTRAQ) and tandem mass tag (TMT) [14,15]. The 2-plex
and 6-plex tandem mass tags (TMTs), through the incorp-
oration of, respectively, one (13 C) and five (13C or 15 N)
stable isotopes, perform relative protein quantification
between two and up to six samples [16]. This method is
successfully used to screen for biomarkers in periodon-
tal disease, colorectal cancer [15], breast cancerand so
on [17,18].
In this study, we used TMT label combined with LC-
MS/MS to compare the expression level of plasma mem-
brane proteins between a pair of “normal” and gastric
cancer tissues, thereby allowing identification of plasma
membrane-associated biomarkers. Our data revealed flo-
tillin 1 plasma membrane protein to be a potential bio-
marker for GC detection.
Methods
Patient samples
GC samples with stage I tumors((AJCC 6th Edition Stage
I disease, with minimal depth of invasion into mucosa and
no metastatic lymph nodes) and matched normal tissue
samples (50–200 mg) were obtained from surgical resec-
tion specimens at the department of pathology, snap fro-
zen in liquid nitrogen, and stored at -80°C until use and
subjected to routine pathological examination at Jiangsu
province hospital. The patients’ age ranged from 32 to
90 years, only 12 patients were GC and were available for
further studies. Written informed consent was obtainedfrom each patient before surgery. This study was approved
by the Ethics Committee of Nanjing Medical University
with an Institutional Review Board (IRB) number of 2012-
NFLZ-32. The tumor and control samples were pooled
separately and subjected to proteomic analysis.Plasma membrane purification and protein lysis
Plasma membrane was enriched as previously described
[19]. Briefly, tissues were lysed by hypotonic buffer
(10 mM Trisbase, 1.5 mM MgCl2, 10 mM NaCl, pH 6.8)
for 5 min followed by centrifugation at 300 × g for
5 min, then resuspended in gradient buffer (0.25 M Su-
crose, 10 mM HEPES, 100 mM Succinic acid, 1 mM
EDTA, 2 mM CaCl2, 2 mM MgCl2, pH7.4) and homoge-
nized. The homogenate was centrifuged at 1,000 × g for
10 min and the supernatant was collected. Subsequently,
the supernatant was centrifuged at 100 000 × g for
30 min. The pellet was purified membranes which were
resuspended in 2 mL gradient buffer by homogenization
and mixed with 1.9 mL Percoll (Amersham Biosciences,
Uppsala,Sweden) containing 10% PBS and 0.19 mL
2.5 M sucrose in an Easy-Seal tube (polyallomer, 5 mL,
Sorvall). The tube was filled with gradient buffer, capped
and centrifuged at 120 000 × g for 15 min. The pellet was
washed with ice-cold PBS three times and suspended in
150 μl of SDS lysis buffer and stored at −80°C. The protein
concentrations were determined by the Bradford method.
Protein digestion and peptide tandem mass tag(TMT)
labeling
Protein digestion and TMT labeling were done as previ-
ously described [20]. 1 mg of plasma membrane protein
from normal or GC samples was reduced with 10 mM
DTT at 60°C for 1 h, alkylated with 55 mM IAA for 45
min at room temperature in the dark and digestion with
trypsin overnight at 37°C. Tryptic peptides were desalted
and then dried in vacuo (Speed Vac, Eppendorf ). 20 μg
of proteins was labeled for 1 h at room temperature by
adding 5 μL of the TMT reagent. The peptides were la-
beled with isobaric tags and mixed at 1:1 ratio based on
total peptide amount. The TMT labeled proteins were
stored at -80°C until used.
SCX fractionation separation
SCX fractionation separation was done as previously de-
scribed [20]. Peptide mixtures were resuspended in
10 mM NH4COOH, 5% ACN( pH 2.7), and subjected to
cation ion exchange columns (1 mm ID × 10 cm packed
with Poros 10 S, DIONEX, Sunnyvale,CA, USA) with
the UltiMate® 3000 HPLC system. The separation was
performed by applying a two-buffer system. Buffers A
and B were prepared as follows: buffer A, 5 mM ammo-
nium formate, 5% ACN (pH = 2.7); buffer B, 800 mM
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gradient was employed: 0% to 30% B for 21 min, 30% to
56% B for 7 min, 56% B to 100% B for 1 min, 100% B for
3 min, 100% B to 0% for 1 min and 0% for 20 min before
the next run. Twenty fractions in total were collected
and lyophilized.
Mass spectrometry analysis
Mass spectrometry analysis was done as previously de-
scribed [21]. The labeled peptides were analyzed on the
LTQ Orbitrap-Velos instrument (Thermo Fisher, USA)
connecting to a Nano ACQUITY UPLC system via a
nanospray source. The reverse-phase separation of pep-
tides was performed using the buffer A(2% ACN, 0.5%
acetic acid) and buffer B (80% ACN, 0.5% acetic acid); the
gradient was set as following: 4% to 9% buffer B for 3 min,
9% to 33% buffer B for 170 min, 33% to 50% buffer B for
10 min, 50% to 100% buffer B for 1 min, 100% buffer B for
8 min, 100% to 4% buffer B for 1 min. For analysis of
plasma membrane proteins, one full scan was followed by
the selection of the eight most intense ions for collision-
induced dissociation (CID) fragmentation (collision energy
35%). The most intense product ion from the MS2 step
was selected for higher energy collision-induced dissoci-
ation (HCD)-MS3 fragmentation.
Protein identification and quantification
Protein identification and quantification were done as
previously described [21]. Maxquant (version 1.2.2.5)
was used to identify the raw spectra acquired from pre-
cursor ions as described [22]. Search parameters were
set as following: precursor mass tolerance of ± 20 parts
per million (ppm); 0.5-dalton product ion mass toler-
ance; trypsin digestion; up to two missed cleavages; car-
bamidomethylation (+57.02146 Da) on cysteine, TMT
reagent adducts (+229.162932 Da) on lysine and peptide
amino termini were set as a fixed modification; and me-
thionine oxidation (+15.99492 Da) was set as a variable
modification. False discovery rates (FDR) of the identi-
fied peptides and proteins were estimated by searching
against the database with the reversed amino acid se-
quence. Only peptides with at least six amino acids in
length and an FDR of 1% were considered to be success-
fully identified. Relative protein abundance ratios be-
tween two groups were calculated from TMT reagent
reporter ion intensities from HCD spectra. For TMT la-
beling, each peptide channel was re-normalized by the
sum across channels. The protein intensity was calcu-
lated as the median of normalized intensity of the corre-
sponding peptides. The mean and standard deviation for
each protein across subjects was calculated, and Perseus
was used to perform statistical comparisons. One-way
analysis of variance (ANOVA) was used to calculate sig-
nificant differences in abundance among groups. Apermutation-based FDR value less than 0.05 was consid-
ered significant.
Ingenuity pathway analysis
To further explore the significance of the differentially
expressed plasma membrane proteins, Ingenuity® Pathway
Analysis (IPA; Ingenuity® Systems, www.ingenuity.com/)
was used to search the relevant molecular functions, cellu-
lar processes and pathways of these identified proteins
during the pathological changes of GC. Associated net-
works of differentially expressed plasma membrane
proteins were generated, along with a score represent-
ing the log probability of a particular network being
found by random chance. Top canonical pathways asso-
ciated with the uploaded data were presented, along
with a p-value. The p-values were calculated using
right-tailed Fisher’s exact tests.
Western blot analyses
Lysates from normal or GC plasma membrane samples
were separated on 11.5% SDS-PAGE gels and then the
proteins were transferred to nitrocellulose membranes,
blocked in TBST containing 5% nonfat milk powder for
4 hour and incubated overnight with primary antibodies
against Na+/K+-ATPase(Abcam Ab76020, 1:1000), prohibi-
tin(Abcam Ab28172, 1:1000), Golgi 58(Abcam Ab27043,
1:500), histone H2A(Abcam Ab18255, 1:1000), sigma
non-opioid intracellular receptor 1(Abcam Ab160924,
Cambridge, UK; 1:1000), flotillin 1(Abcam Ab41927,
1:500), CD36 (Abcam Ab78054, 1:500) and CD9 mol-
ecule (Abcam Ab65230, 1:500), then washed three
times with TBST. The membranes were incubated for 1
hour with alkaline phosphatase (AP)-conjugated anti-
mouse or rabbit IgG. The protein levels were evaluated
by the detection of activity of alkaline phosphatase
using a Lumi-Phos kit (Pierce Biotechnology). The visu-
alized bands of western blot were quantified with Bio-
Rad QUANTITY ONE software. The volumes of target
bands were normalized to GAPDH. The average abso-
lute intensity and the standard deviation were deter-
mined. The protein ratio was determined using these
averaged values. Student’s T-test was used to generate
p values. Significant difference was recognized as a p value
less than 0.05.
Immunohistochemistry and tissue microarray
For expression studies of human flotillin 1 in clinical
samples, we used tissue microarrays purchased from
Biomax, Inc. [ST1004 and bST801a)] containing cores
from a total of 85 different cases of GC with matched
adjacent normal tissues and an additional 10 normal
only tissues. IHC of tissue arrays was done as described
previously. Flotillin 1 protein expression was assessed
using a previously described semiquantitative scoring
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(scale 0 to 3) and the percentage of positive cells (0 to
100%), which, when multiplied, generate a score ranging
from 0 to 300. Statistical analysis was done using SPSS
18.0. The t test was performed at 95% confidence.
Results
Detection of plasma membrane proteins in GC and
adjacent normal tissues
The experimental workflow of this study is shown in
Figure 1. To discover plasma membrane protein alter-
ations associated with GC, six pools of plasma membrane
samples (three controls and three GC) were generated by
pooling samples from 4 subjects for each pool. The purity
of the plasma membrane after Percoll density gradient
centrifugation was detected by western blot analysis.
Figure 2 indicated that the plasma membrane was highly
enriched in the marker, Na+/K+-ATPase, compared to the
total lysis fraction. A total of 501 proteins were identified
in the workflow (Additional file 1: Table S1). To furtherFigure 1 Schematic representation of the strategy used to identify the diffassess the efficacy of the protocol for the enrichment of
plasma membrane proteins, the subcellular locations and
functions were cataloged according to the gene ontology
(GO) component annotations from literatures. Figure 3
showed that 175 proteins (about 35%) have been assigned
as plasma membrane or membrane-associated proteins.
Of the remaining proteins with subcellular annotation, ap-
proximately 16.9% of the identified proteins are extracellu-
lar, and 20.1% proteins locate in cytoplasm. 10% proteins
locate in mitochondria and 11.5% proteins are nuclear or
nuclear associated proteins. Other 6.5% proteins are
mainly from cytoskeleton and endoplasmic reticulum.
Quantification of plasma membrane proteins in GC and
adjacent normal tissues
Proteins were labeled with TMT reagents and analyzed
using tandem mass spectrometry to screen for the differ-
entially expressed proteins between GC and adjacent
normal tissues. To increase the coverage of protein iden-
tifications and the confidence of the data generated,erentially expressed proteins in GC tissues.
Figure 2 Western blot analysis of the plasma membrane from GC and control tissues after Percoll density gradient centrifugation; The same amount
of proteins (50 μg) was loaded on each lane.
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TMT reagents 126, 127 and 128 respectively; pools of
GC tissues were labeled with TMT reagents 129, 130
and 131 respectively. The relative quantification analysis
by Maxquant 1.2.2.5 software comes with statistical ana-
lysis, however, most methods are prone to technical vari-
ation, so we included an additional 1.5-fold cut off for
all TMT ratios to add stringency when classifying
proteins as up- or down-regulated. A total of 205 differ-
entially expressed proteins proteins were identified with
95% confidence (Additional file 2: Table S2). Of these,
82 plasma membrane proteins were found to have >1.5-
fold difference in expression between the GC and adjacent
normal tissues (Table 1). 24 proteins were downregulated
in gastric cancer, whereas 58 were overexpressed com-
pared to adjacent normal tissues. The plasma membrane/
plasma membrane -associated proteins comprised about
40% of the total proteins detected. The mass spectra of
four representative proteins (sigma non-opioid intracellu-
lar receptor 1, flotillin 1, CD36 and CD9 molecule) were
shown in Figure 4.Figure 3 The subcellular locations of the identified proteins from GC and nFunctional characteristics of the proteins detected in GC
and adjacent normal tissues
To better appreciate the molecular and functional char-
acteristics of the 82 differentially expressed plasma mem-
brane or membrane-associated proteins, these proteins
were subjected to IPA analysis for further identification of
important biological processes that they were significantly
involved in. The over-represented biological processes,
molecular functions, and canonical pathways were gen-
erated based on information contained in the Ingenuity
Pathways Knowledge Base. We found that the top three
significant biological processes of the differentially
expressed proteins in our study were networks describ-
ing 1) cancer, renal and urological system development
and function, tissue morphology; 2) cell-to-cell signaling
and interaction, infectious disease, cellular function and
maintenance; 3) cellular assembly and organization,
nervous system development and function, cellular
movement. For molecular and cellular functions, the
data indicated that many proteins involved in cellular
function and maintenance, cell-to-cell signaling andormal tissues according to the GO annotations and literature.
Table 1 Differentially regulated plasma membrane proteins identified in GC tissues
Accession No. Gene symbols Description TMT ratio P value Function
Q12959 DLG1 discs, large homolog 1 (Drosophila) -8.78 1.28E-05 kinase
G8JLH6 CD9 CD9 molecule -3.723 7.04E-02 other
P30453 HLA-A major histocompatibility complex, class I, A -2.903 7.40E-04 other
O95810 SDPR serum deprivation response -2.623 1.69E-09 other
P48960 CD97 CD97 molecule -2.615 3.74E-01 G-protein coupled receptor
Q16853 AOC3 amine oxidase, copper containing 3 -2.314 1.11E-10 enzyme
E7EWP3 MPZ myelin protein zero -2.266 2.45E-07 other
Q03135 CAV1 caveolin 1, caveolae protein, 22 kDa -2.251 2.43E-10 transmembrane receptor
P41219 PRPH peripherin -2.149 1.65E-08 other
P43121 MCAM melanoma cell adhesion molecule -2.115 1.93E-09 other
Q9HAV0 GNB4 guanine nucleotide binding protein (G protein), beta polypeptide 4 -1.976 9.69E-04 enzyme
Q86UP2 KTN1 kinectin 1 (kinesin receptor) -1.959 7.69E-03 transmembrane receptor
P01859 IGHG2 immunoglobulin heavy constant gamma 2 (G2m marker) -1.844 1.43E-02 other
B7Z2R4 SGCE sarcoglycan, epsilon -1.791 2.91E-02 other
P18206 VCL vinculin -1.685 2.01E-10 enzyme
A0FGR8 ESYT2 extended synaptotagmin-like protein 2 -1.672 2.68E-03 other
P08133 ANXA6 annexin A6 -1.668 1.10E-11 ion channel
O43491 EPB41L2 erythrocyte membrane protein band 4.1-like 2 -1.66 1.05E-08 other
Q14BN4 SLMAP sarcolemma associated protein -1.645 6.33E-04 other
A6NMH8 CD81 CD81 molecule -1.634 3.17E-04 other
Q96CX2 KCTD12 potassium channel tetramerization domain containing 12 -1.559 3.59E-08 ion channel
Q9H223 EHD4 EH-domain containing 4 -1.527 1.30E-03 enzyme
Q13418 ILK integrin-linked kinase -1.526 1.20E-09 kinase
P16671 CD36 CD36 molecule (thrombospondin receptor) -1.501 1.16E-06 transmembrane receptor
P38606 ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A 1.514 3.79E-05 transporter
Q14108 SCARB2 scavenger receptor class B, member 2 1.514 1.92E-08 other
P01903 HLA-DRA major histocompatibility complex, class II, DR alpha 1.521 2.94E-08 transmembrane receptor
Q14444 CAPRIN1 cell cycle associated protein 1 1.529 1.30E-06 other
Q6IAA8 LAMTOR1 late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 1.533 5.18E-03 other
P27216 ANXA13 annexin A13 1.536 3.38E-09 other
Q9Y287 ITM2B integral membrane protein 2B 1.553 7.16E-02 other














Table 1 Differentially regulated plasma membrane proteins identified in GC tissues (Continued)
Q8WVV4 POF1B premature ovarian failure, 1B 1.568 9.94E-09 other
D6RH31 NPNT nephronectin 1.59 1.40E-05 other
Q9P0L0 VAPA VAMP (vesicle-associated membrane protein)-associated
protein A, 33 kDa
1.597 7.50E-06 other
P02786 TFRC transferrin receptor 1.602 3.53E-01 transporter
O00203 AP3B1 adaptor-related protein complex 3, beta 1 subunit 1.619 5.16E-03 transporter
Q00610 CLTC clathrin, heavy chain (Hc) 1.623 6.18E-11 other
P26006 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3
receptor)
1.645 3.24E-08 other
O95292 VAPB VAMP (vesicle-associated membrane protein)-associated protein B and C 1.652 4.17E-05 other
B4DNJ6 STRAP serine/threonine kinase receptor associated protein 1.654 4.56E-03 other
B5MCA4 EPCAM epithelial cell adhesion molecule 1.655 4.47E-03 other
Q14247 CTTN cortactin 1.664 2.58E-06 other
C9JME2 FARP1 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1
(chondrocyte-derived)
1.667 4.07E-10 other
P15144 ANPEP alanyl (membrane) aminopeptidase 1.693 7.85E-10 peptidase
G5EA09 SDCBP syndecan binding protein (syntenin) 1.71 1.01E-06 enzyme
O75955 FLOT1 flotillin 1 1.727 2.09E-02 other
Q86XK7 VSIG1 V-set and immunoglobulin domain containing 1 1.727 1.27E-04 other
P00533 EGFR epidermal growth factor receptor 1.755 2.27E-01 kinase
P17301 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 1.786 1.19E-08 transmembrane receptor
P29992 GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 1.786 7.56E-02 enzyme
C9J6P4 ZC3HAV1 zinc finger CCCH-type, antiviral 1 1.835 3.35E-09 other
P27105 STOM stomatin 1.844 1.31E-04 other
P46977 STT3A STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 1.895 5.89E-05 enzyme
Q9BX66 SORBS1 sorbin and SH3 domain containing 1 1.895 1.62E-08 other
O95563 MPC2 mitochondrial pyruvate carrier 2 1.917 2.32E-08 other
P09496 CLTA clathrin, light chain A 1.926 1.13E-12 other
Q13155 AIMP2 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 1.928 1.03E-07 other
P09497 CLTB clathrin, light chain B 1.954 1.00E-10 other
H9KV28 DIAPH1 diaphanous-related formin 1 1.958 8.62E-04 other
Q99720 SIGMAR1 sigma non-opioid intracellular receptor 1 1.961 3.62E-04 G-protein coupled receptor
P13473 LAMP2 lysosomal-associated membrane protein 2 1.999 5.05E-10 enzyme












Table 1 Differentially regulated plasma membrane proteins identified in GC tissues (Continued)
P11215 ITGAM integrin, alpha M (complement component 3 receptor 3 subunit) 2.012 2.29E-10 transmembrane receptor
P15924 DSP desmoplakin 2.031 8.86E-13 other
Q9UGM3 DMBT1 deleted in malignant brain tumors 1 2.079 2.59E-06 transmembrane receptor
Q93008 USP9X ubiquitin specific peptidase 9, X-linked 2.19 1.22E-01 peptidase
O15400 STX7 syntaxin 7 2.208 1.94E-07 transporter
Q9BXJ0 C1QTNF5 C1q and tumor necrosis factor related protein 5 2.223 2.33E-04 transmembrane receptor
Q9UJZ1 STOML2 stomatin (EPB72)-like 2 2.228 1.06E-04 other
P55011 SLC12A2 solute carrier family 12 (sodium/potassium/chloride
transporter), member 2
2.332 5.91E-11 transporter
O00182 LGALS9 lectin, galactoside-binding, soluble, 9 2.45 1.39E-05 other
Q08380 LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein 2.469 4.66E-06 transmembrane receptor
Q9UGI8 TES testis derived transcript (3 LIM domains) 2.577 1.55E-06 other
Q9NZ01 TECR trans-2,3-enoyl-CoA reductase 2.83 1.45E-07 enzyme
G3V1K3 PON2 paraoxonase 2 2.932 3.93E-06 enzyme
O95841 ANGPTL1 angiopoietin-like 1 3.109 4.33E-04 other
Q92542 NCSTN nicastrin 3.634 3.58E-02 peptidase
O95497 VNN1 vanin 1 3.718 1.00E-08 enzyme
P16144 ITGB4 integrin, beta 4 3.792 2.40E-01 transmembrane receptor
Q96HR9 REEP6 receptor accessory protein 6 3.797 2.70E-08 other












Figure 4 Mass spectra of four representative proteins. (A) sigma non-opioid intracellular receptor 1, (B) flotillin 1, (C) CD 36 and (D) CD9.
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Our results showed that the top three canonical path-
ways of differentially expressed proteins participated in
were virus entry via endocytic pathways, caveolar-
mediated endocytosis signaling and integrin signaling
(Figure 5).
Confirmation of differentially expressed proteins by
western blotting
Western blot analyses were performed on selected can-
didates (sigma non-opioid intracellular receptor 1, flotil-
lin 1, CD 36 and CD9 molecule). These candidates were
chosen based on the plasma membrane markers not
known previously reported to be differentially expressed
in gastric cancer since the key objective of this study is
to identify potential biomarkers of GC. Figure 6 shows
that the up- or down-regulation trend of candidate
proteins between GC and normal tissue revealed by the
Western blot data is congruent with that revealed by
quantitative proteomic method. A positive correlation
for the direction of changes was observed. The result of
western blotting provides evidence that the TMT label-
ing method for the large scale protein quantification was
reliable.
Flotillin 1 is relevant to clinical gastric cancer as a
potential target
To assess the clinical relevance, we examined the ex-
pression of flotillin 1 in tissue microarrays containing 85
matched normal and gastric cancer tissues by immuno-
histochemistry (Additional file 3: Table S3). The TMA
also includes ten additional unmatched normal gastric
tissues. The expression levels of flotillin 1 across the
clinical samples are presented in a distribution plot
(Figure 7). Two-samples t test revealed that the expres-
sion of flotillin 1 in cancer/tumor samples is significantlyFigure 5 Ingenuity Pathway Analysis of proteins that were significantly altehigher than that of noncancer/normal tissues (p < 0.01).
In addition, 50.5% (43/85) of the matched cases showed
higher flotillin 1 expression in the tumor compared to
normal tissues while only 13% of the matched cases
showed the reverse trend (Figure 7). 36.5% of the
matched cases had no detectable level of flotillin 1. The
expression data from clinical samples analysis revealed
that the upregulation of flotillin 1 has quite a high pene-
trance (>40%) in gastric cancer. Representative images of
the immunohistochemistry of flotillin 1 in 2 sets of
matched normal and gastric cancer tissues are shown in
Figure 7.
Discussion
Although the prevalence of gastric cancer is declining
and varying geographically, it remains one of the most
common cancers in worldwide [1,2,23]. Five-year sur-
vival rates have ranged from 90% to less than 5%, mainly
depending on the stage of diagnosis [24]. If gastric can-
cer can be detected and treated in early stages(stage I),
the five-year survival rate is better than 90%. Unfortu-
nately, no reliable diagnostic biomarkers exist for early
detection of gastric cancer [25]. In order to dig out new
drug targets or biomarkers, methods such as subcellular
proteome research were adopted to offer new insights
[26]. Because most of the drug targets are proteins
located in the plasma membrane, we specifically focused
our study on the plasma membrane proteome [27]. In
this research, we used a percoll/sucrose density gradient
approach for plasma membrane enrichment combined
with TMT technology using nano liquid chromatog-
raphy–tandem mass spectrometry analysis to identify
specifically differentially expressed proteins in GC tissues
compared with adjacent normal tissues. Based on the
stringent criteria, in the present study, 82 plasma mem-
brane proteins were identified as differentially expressedred in pathways.
Figure 6 A representative western blot analysis from one of the pools
to validate results from TMT labeling. (A) Plasma membrane proteins
of GC and control tissues were analyzed by Western blot using
antibodies against sigma non-opioid intracellular receptor 1, flotillin 1,
CD 36 and CD9. (B) The levels of non-opioid intracellular receptor 1,
flotillin 1, CD 36 and CD 9 were normalized relative to GAPDH levels.
Data represent mean values ± SEM.
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24 were decreased. Discs, large homolog 1 protein is the
most decreased protein and transmembrane 4 L protein is
the most increased protein in GC tissue. Some low-
abundance plasma membrane proteins such as potassium
channel tetramerization domain containing 12, sigma non-
opioid intracellular receptor 1 were found.
Previously studies have found a number of markers
(e.g. annexin A6, caveolin 1, epidermal growth factor re-
ceptor, integrin beta 4) measured in the first and early
second trimesters which are associated with the diagno-
sis of GC [28-35]. Annexin A6 functions as a tumor sup-
pressor in gastric cancer cells through the inhibition of
Ras/MAPK signaling [36]. Caveolin-1 promotes gastriccancer progression by up-regulating epithelial to mesen-
chymal transition by crosstalk of signalling mechanisms
under hypoxic condition. Human epidermal growth fac-
tor receptor (EGFR) which belongs to EGFR family is
overexpressed in a significant proportion of cases of GC
to promote metastasis of cancer [37]. Integrin beta 4 ex-
pressions are positively correlated in gastric cancer cell
lines and tissues [33]. The survival analyses show that
the expression of integrin beta 4 is associated with poor
outcomes in gastric cancer patients [38]. Our prospect-
ive studies have confirmed these validated biomarkers.
In addition, many potentially novel biomarkers of GC
were found, such as CD36,CD81,CD9,CD97 and so on.
As demonstrated here, TMT labeling combined with
LC-MS/MS is a powerful tool for the identification of
membrane protein biomarkers of GC.
It is reported that endocytosis is enhanced and skewed
in cancer cells [39]. Endocytosis is multicomponent
process which entails selective packaging of cell-surface
proteins, such as receptors for cytokines and adhesion
components, in cytoplasmic vesicles (endosomes). The
series of sorting events that determines the fate of inter-
nalized proteins, either degradation in lysosomes or re-
cycling back to the plasma membrane. Many proteins
involved in endocytosis have been reported to be per-
turbed in human cancers [40]. In this research, proteins
such as caveolin 1, epidermal growth factor receptor,
major histocompatibility complex, integrin, cortactin,
transferrin receptor, ubiquitin specific peptidase 9 partic-
ipated in caveolae /clathrin mediated endocytosis were
found as differentially expressed proteins. Caveolae, sub-
sarcolemmal membrane compartments, have been impli-
cated in signal transduction and vesicular trafficking
[41]. Caveolae are capable of removing proteins from the
plasma membrane by sequestration and endocytotic
mechanism [42]. Clathrin-mediated endocytosis is the
endocytic portal into cells through which cargo is pack-
aged into vesicles with the aid of a clathrin coat [43].
Clathrin heavy chain and cortactin have been reported
to have their expression levels changed in breast cancer
[44,45]. These two proteins were also found overex-
pressed in GC tissues in this research. However, proteins
such as flotillin 1 involved in clathrin-mediated endo-
cytosis have not been reported to differentially expressed
in GC tumours in previous researches. The flotillin pro-
tein family has been demonstrated to be involved in the
development and progression of various cancers. Flotillin
1 is highly conserved protein that localize into specific
cholesterol rich microdomains in cellular membranes
[46]. Flotillin-2 is a major protein from caveolae/lipid raft
and is involved in epidermal cell adhesion. Recent findings
have revealed that flotillin1 and flotillin 2 are frequently
overexpressed in various types of human cancers includ-
ing lung adenocarcinoma, nasopharyngeal carcinoma [47],
Figure 7 Immunohistochemistry of flotillin 1 in tissue microarrays of clinical gastric samples. A total of 85 matched normal and cancer tissues
plus addition 10 normal tissues were analyzed. (A) Distribution plot of the IHC scores of flotillin 1 in individual normal and gastric cancer samples.
(B) Representative IHC images (10× magnification) of flotillin 1 in 2 matched gastric cancer and normal tissues.
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patocellular carcinoma [48]. Importantly, recent researches
have suggested that the flotillin 2 protein expression is sig-
nificantly correlated with cancer progression and poor
prognosis in gastric carcinomas, probably due to its role in
the regulation of cell proliferation, migration, and invasion
in gastric carcinoma cells [49,50]. However, flotillin 2 was
not identified in our research. After analysis of spotted
sequences, we found the peptide similarities of flotillin 1
and 2 were low, as described in supplemental Figure 1
(Additional file 4: Figure S1). In this research, abnormal ex-
pression of flotillin 1 has been also confirmed in clinical
gastric cancers in this study. For the first time, the associ-
ation of flotillin 1 in gastric cancer has been established in
our study, suggesting that flotillin 1 is a promising candi-
date for future biomarker development for gastric cancer.
Conclusion
With the help of proteomics analysis, we discovered that a
series of plasma membrane proteins showed an alteredexpression level in GC tissues. 82 plasma membrane pro-
teins with functional relevance to GC were found to be
significantly different between GC and control tissues.
Our approach allowed us to identify a number of markers
(e.g. annexin A6, caveolin 1 ,epidermal growth factor re-
ceptor, integrin beta 4) that were previously reported as
biomarkers of GC. Additionally, we have presented several
potential biomarkers participated in endocytosis pathway
and integrin signaling pathway were firstly identified dif-
ferentially expressed in GC samples. Our findings also
suggest that flotillin 1 may be a novel biomarker for
GC.These findings will not only benefit early diagnosis of
this cancer at the molecular level but also improve our un-
derstanding of the initiation and development of GC.Additional files
Additional file 1: Table S1. All of identified proteins in this research.
Gao et al. BMC Cancer  (2015) 15:367 Page 13 of 14Additional file 2: Table S2. The list of the differentially expressed
proteins in GC samples.
Additional file 3: Table S3. Raw IHC scores of climnical samples used
in TMAS.
Additional file 4: Figure S1. CLUSTAL 2. 1 multiple sequence alignment.
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